BACKGROUND There are many adverse reactions in the treatment of allergic rhinitis(AR)mainly with conventional drugs.Leukotriene receptor antagonists,glucocorticoids and nasal antihistamines can all be used as first-li...BACKGROUND There are many adverse reactions in the treatment of allergic rhinitis(AR)mainly with conventional drugs.Leukotriene receptor antagonists,glucocorticoids and nasal antihistamines can all be used as first-line drugs for AR,but the clinical effects of the three drugs are not clear.AIM To examine the impact of glucocorticoids,antihistamines,and leukotriene receptor antagonists on individuals diagnosed with AR,specifically focusing on their influence on serum inflammatory indexes.METHODS The present retrospective study focused on the clinical data of 80 patients diagnosed and treated for AR at our hospital between May 2019 and May 2021.The participants were categorized into the control group and the observation group.The control group received leukotriene receptor antagonists,while the observation group was administered glucocorticoids and antihistamines.Conducted an observation and comparison of the symptoms,physical sign scores,adverse reactions,and effects on serum inflammatory indexes in two distinct groups of patients,both before and after treatment.RESULTS Subsequent to treatment,the nasal itching score,sneeze score,runny nose score,nasal congestion score,and physical signs score exhibited notable discrepancies(P<0.05),with the observation group demonstrating superior outcomes compared to the control group(P<0.05).The interleukin(IL)-6,IL-10,tumor necrosis factor-alpha,Soluble Intercellular Adhesion Molecule-1,Leukotriene D4 after treatment were significantly different and the observation group It is better than the control group,which is statistically significant(P<0.05).Following the intervention,the incidence of adverse reactions in the observation group,including symptoms such as nasal dryness,discomfort in the throat,bitter taste in the mouth,and minor erosion of the nasal mucosa,was found to be 7.5%.This rate was significantly lower compared to the control group,which reported an incidence of 27.5%.The difference between the two groups was statistically significant(P<0.05).CONCLUSION Glucocorticoids and antihistamines have obvious therapeutic effects,reduce serum inflammatory index levels,relieve symptoms and signs of patients,and promote patients'recovery,which can provide a reference for clinical treatment of AR.展开更多
目的探讨白三烯受体拮抗剂(leukotriene receptor antagonists,LTRA)与ATP结合盒亚家族C1(ATP-binding cassette sub-family C member 1,ABCC1)基因rs119774位点、溶质载体有机阴离子转运蛋白家族成员2B1(solute carrier organic anion ...目的探讨白三烯受体拮抗剂(leukotriene receptor antagonists,LTRA)与ATP结合盒亚家族C1(ATP-binding cassette sub-family C member 1,ABCC1)基因rs119774位点、溶质载体有机阴离子转运蛋白家族成员2B1(solute carrier organic anion transporter family member 2B1,SLCO2B1)基因rs12422149位点的单核苷酸多态性(single nucleotide polymorphism,SNP)治疗汉族儿童支气管哮喘疗效的相关性。方法选取2019年4月至2021年12月于福建中医药大学附属厦门市中医院就诊的4~13岁汉族支气管哮喘患儿100例为研究对象,采用一代测序法对患儿的ABCC1基因rs119774位点、SLCO2B1基因rs12422149位点进行检测,分析比较2个位点的SNP分布情况。入组患儿均应用LTRA进行治疗,分别于治疗前与治疗12周时进行肺通气功能及脉冲震荡功能检测,并评估临床症状控制水平,分析患儿疗效与SNP的相关性。统计学方法采用t检验、χ^(2)检验。结果治疗前与治疗12周后,ABCC1基因rs119774位点CC型哮喘患儿应用孟鲁司特钠第1秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))[(87.0±16.5)与(93.2±15.1)L,t=-2.071,P=0.038]、峰值呼气流速(peak expiratory flow,PEF)[(77.1±16.9)与(86.5±16.6)L/s,t=-3.233,P=0.001]和25%肺活量的呼气流速(forced expiratory flow 25,FEF25)[(69.6±18.8)与(78.1±19.9)L/s,t=-1.985,P=0.047]均有明显提高,脉冲震荡各项指标显著改善(P<0.05)。治疗后SLCO2B1基因rs12422149位点AA型肺功能指标PEF高于治疗前[(79.0±16.0)与(93.0±9.4)L/s,t=-2.547,P=0.011],治疗后GG型肺功能各指标显著高于治疗前(P<0.05)。ABCC1治疗前后控制率[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001];治疗前后SLCO2B1基因rs119774位点AA型、AG型、GG型的控制率分别为[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001]、[53%(8/15)与80%(12/15),93%(14/15)χ^(2)=12.786,P=0.002]与[56%(23/41)与78%(32/41),78%(32/41),χ^(2)=6.583,P=0.037]与[73%(32/44)与77%(34/44),73%(32/44),χ^(2)=6.471,P=0.039],均显著改善。结论LTRA治疗汉族支气管哮喘患儿与ABCC1、SLCO2B1基因SNP的效果存在相关性。展开更多
目的观察儿童轻中度阻塞性睡眠呼吸暂停低通气综合征(OS A H S)抗炎治疗的临床疗效,分析儿童OSAHS与炎症的关系。方法选取2016年1-11月经多导睡眠监测(PSG)确诊的轻中度OSAHS患儿50例,记录病史、腺样体大小、扁桃体大小、OSA-18问卷评分...目的观察儿童轻中度阻塞性睡眠呼吸暂停低通气综合征(OS A H S)抗炎治疗的临床疗效,分析儿童OSAHS与炎症的关系。方法选取2016年1-11月经多导睡眠监测(PSG)确诊的轻中度OSAHS患儿50例,记录病史、腺样体大小、扁桃体大小、OSA-18问卷评分,给予糠酸莫米松鼻喷剂联合口服孟鲁司特治疗12周,治疗结束后复查PSG、腺样体大小、扁桃体大小及OSA-18问卷,并对治疗前后的数据进行比较。结果在50例患儿中,轻度OSAHS37例,中度OSAHS 13例;共治愈19例(38%),其中轻度OSAHS 17例,中度OSAHS 2例;显效14例(28%);有效5例(10%);总体有效率为76%(38/50)。与治疗前比较,轻度OSAHS患儿治疗后阻塞性呼吸暂停指数(OAI)、混合性呼吸暂停指数(MAI)降低,腺样体、扁桃体体积缩小,OSA-18评分降低,差异均有统计学意义(P<0.05)。中度OSAHS患儿治疗后OAI较治疗前明显降低(P<0.05),而腺样体、扁桃体体积及OSA-18评分、MAI与治疗前比较差异无统计学意义(P>0.05)。扁桃体体积变化与PSG参数变化无明显相关性。结论抗炎治疗可明显改善OSAHS患儿的PSG指数、腺样体和扁桃体体积及生活质量,对轻度OSAHS患儿疗效更为显著。展开更多
文摘BACKGROUND There are many adverse reactions in the treatment of allergic rhinitis(AR)mainly with conventional drugs.Leukotriene receptor antagonists,glucocorticoids and nasal antihistamines can all be used as first-line drugs for AR,but the clinical effects of the three drugs are not clear.AIM To examine the impact of glucocorticoids,antihistamines,and leukotriene receptor antagonists on individuals diagnosed with AR,specifically focusing on their influence on serum inflammatory indexes.METHODS The present retrospective study focused on the clinical data of 80 patients diagnosed and treated for AR at our hospital between May 2019 and May 2021.The participants were categorized into the control group and the observation group.The control group received leukotriene receptor antagonists,while the observation group was administered glucocorticoids and antihistamines.Conducted an observation and comparison of the symptoms,physical sign scores,adverse reactions,and effects on serum inflammatory indexes in two distinct groups of patients,both before and after treatment.RESULTS Subsequent to treatment,the nasal itching score,sneeze score,runny nose score,nasal congestion score,and physical signs score exhibited notable discrepancies(P<0.05),with the observation group demonstrating superior outcomes compared to the control group(P<0.05).The interleukin(IL)-6,IL-10,tumor necrosis factor-alpha,Soluble Intercellular Adhesion Molecule-1,Leukotriene D4 after treatment were significantly different and the observation group It is better than the control group,which is statistically significant(P<0.05).Following the intervention,the incidence of adverse reactions in the observation group,including symptoms such as nasal dryness,discomfort in the throat,bitter taste in the mouth,and minor erosion of the nasal mucosa,was found to be 7.5%.This rate was significantly lower compared to the control group,which reported an incidence of 27.5%.The difference between the two groups was statistically significant(P<0.05).CONCLUSION Glucocorticoids and antihistamines have obvious therapeutic effects,reduce serum inflammatory index levels,relieve symptoms and signs of patients,and promote patients'recovery,which can provide a reference for clinical treatment of AR.
文摘目的探讨白三烯受体拮抗剂(leukotriene receptor antagonists,LTRA)与ATP结合盒亚家族C1(ATP-binding cassette sub-family C member 1,ABCC1)基因rs119774位点、溶质载体有机阴离子转运蛋白家族成员2B1(solute carrier organic anion transporter family member 2B1,SLCO2B1)基因rs12422149位点的单核苷酸多态性(single nucleotide polymorphism,SNP)治疗汉族儿童支气管哮喘疗效的相关性。方法选取2019年4月至2021年12月于福建中医药大学附属厦门市中医院就诊的4~13岁汉族支气管哮喘患儿100例为研究对象,采用一代测序法对患儿的ABCC1基因rs119774位点、SLCO2B1基因rs12422149位点进行检测,分析比较2个位点的SNP分布情况。入组患儿均应用LTRA进行治疗,分别于治疗前与治疗12周时进行肺通气功能及脉冲震荡功能检测,并评估临床症状控制水平,分析患儿疗效与SNP的相关性。统计学方法采用t检验、χ^(2)检验。结果治疗前与治疗12周后,ABCC1基因rs119774位点CC型哮喘患儿应用孟鲁司特钠第1秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))[(87.0±16.5)与(93.2±15.1)L,t=-2.071,P=0.038]、峰值呼气流速(peak expiratory flow,PEF)[(77.1±16.9)与(86.5±16.6)L/s,t=-3.233,P=0.001]和25%肺活量的呼气流速(forced expiratory flow 25,FEF25)[(69.6±18.8)与(78.1±19.9)L/s,t=-1.985,P=0.047]均有明显提高,脉冲震荡各项指标显著改善(P<0.05)。治疗后SLCO2B1基因rs12422149位点AA型肺功能指标PEF高于治疗前[(79.0±16.0)与(93.0±9.4)L/s,t=-2.547,P=0.011],治疗后GG型肺功能各指标显著高于治疗前(P<0.05)。ABCC1治疗前后控制率[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001];治疗前后SLCO2B1基因rs119774位点AA型、AG型、GG型的控制率分别为[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001]、[53%(8/15)与80%(12/15),93%(14/15)χ^(2)=12.786,P=0.002]与[56%(23/41)与78%(32/41),78%(32/41),χ^(2)=6.583,P=0.037]与[73%(32/44)与77%(34/44),73%(32/44),χ^(2)=6.471,P=0.039],均显著改善。结论LTRA治疗汉族支气管哮喘患儿与ABCC1、SLCO2B1基因SNP的效果存在相关性。
文摘目的观察儿童轻中度阻塞性睡眠呼吸暂停低通气综合征(OS A H S)抗炎治疗的临床疗效,分析儿童OSAHS与炎症的关系。方法选取2016年1-11月经多导睡眠监测(PSG)确诊的轻中度OSAHS患儿50例,记录病史、腺样体大小、扁桃体大小、OSA-18问卷评分,给予糠酸莫米松鼻喷剂联合口服孟鲁司特治疗12周,治疗结束后复查PSG、腺样体大小、扁桃体大小及OSA-18问卷,并对治疗前后的数据进行比较。结果在50例患儿中,轻度OSAHS37例,中度OSAHS 13例;共治愈19例(38%),其中轻度OSAHS 17例,中度OSAHS 2例;显效14例(28%);有效5例(10%);总体有效率为76%(38/50)。与治疗前比较,轻度OSAHS患儿治疗后阻塞性呼吸暂停指数(OAI)、混合性呼吸暂停指数(MAI)降低,腺样体、扁桃体体积缩小,OSA-18评分降低,差异均有统计学意义(P<0.05)。中度OSAHS患儿治疗后OAI较治疗前明显降低(P<0.05),而腺样体、扁桃体体积及OSA-18评分、MAI与治疗前比较差异无统计学意义(P>0.05)。扁桃体体积变化与PSG参数变化无明显相关性。结论抗炎治疗可明显改善OSAHS患儿的PSG指数、腺样体和扁桃体体积及生活质量,对轻度OSAHS患儿疗效更为显著。